To evaluate immunogenicity consistency between three consecutive batches of commercial-scale productions for Sinovac Rabies vaccine
Participants are able to understand and voluntarily sign the Informed Consent Form;
Able to provide legal identity documents;
Age 18 to 45 years;
Stable health status (defined as stable underlying disease status within 3 months prior to enrollment, i.e., no change in original treatment or hospitalization due to disorder aggravation);
For subjects with pyrexia on the scheduled vaccination day, axillary temperature >37.3℃ before vaccination;
Previous use of anti-Rabies Passive immunization preparations (including but not limited to equine-derived Immunoglobulin ERIG, human-derived Immunoglobulins HRIG, and rabies monoclonal antibody preparations, etc.) or previous Vaccination with human Rabies Vaccine;
Individuals with mammalian animal bites/scratches (e.g., dog/cat) and broken skin (i.e., Category II or higher exposure) within the past year.;
Female participants who are lactating or pregnant (including those with a positive urine pregnancy test).
Parallel
Sinovac rabies vaccine
Biological/VaccineThree batchs of Rabies Vaccine (Serum-free Vero Cell), Freeze-dried using five doses of PEP schedules
Geometric Mean Concentration (GMC) of rabies neutralizing antibodies among susceptible participants (RVNA titer <0.5 IU/mL before vaccination) in each group
GMC of rabies neutralizing antibody
Seroconversion Rate of rabies neutralizing antibody
Incidence of adverse reactions
Incidence of serious adverse events
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
